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Human MDRI cDNA was introduced into the human cultured cells KB-3-l and Sclll-_osucchuronl?‘ces pombe pmdl null mutant KN3. The drug 
sensitivity of KB-G2 and KN3/pgp, expressmg human P-glycoprotein, was exammed. KB-G2 was resistant to the peptlde antibiotics valinomycin 
and gramicidin D as well as having a typical multidrug resistance (MDR) phenotype. KN3/pgp was resistant to valinomycin and actinomycin D. 
but not to adriamycm. The ATP-hydrolysis-defiaent mutant did not confer KN3 resistance to these antiblotlcs. Human P-glycoprotein expressed 
in S. pombe seemed to lack N-glycosylation. The N-glycosylation-deficient mutant, however. conferred a typical MDR phenotype on KB-3-l. These 
results suggest that human P-glycoprotein fun&Ions as an efflux pump of vahnomycin and actinomycin D m the membrane of S. pomhe 
P-glycoprotein: Multidrug resistance: Yeast. Schi=osacchororr~yces pornhe: ATP hydrolysis; Glycosylatlon 
1. INTRODUCTION 
The development of multidrug resistance (MDR) is 
a major obstacle in cancer chemotherapy. Typical 
MDR acts against various anticancer drugs that have 
no structural similarity. P-glycoprotein is a 170-kDa 
membrane protein coded by the MDRl gene in humans, 
and is believed to be involved in MDR. P-glycoprotein 
binds various anticancer drugs including Wzca alka- 
loids, anthracyclines and actinomycin D, and pumps 
them out of the cell using the energy from ATP hydrol- 
ysis [ 1,2]. 
P-glycoprotein also interacts with peptides. Overpro- 
duction of human P-glycoprotein confers resistance 
against the peptide ionophore antibiotic gramicidin D 
[3]. Chinese hamster and human P-glycoproteins were 
reported to be capable of transporting a tripeptide. N- 
acetyl-leucyl-leucyl-norleucinal, which is an inhibitor of 
various intracellular proteases [4]. It was also reported 
that the mouse mdr3 gene but not the human MDRl 
gene, carrying the G185V mutation, could complement 
yeast STE6, which is a homologue of mammalian mdr 
genes and mediates export of a-factor mating peptide in 
Succharomyces cerevisiue [5,6]. By using a transcellular 
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transport system, it was shown that cyclosporin A, a 
cyclic undecapeptide with strong immunosuppressive 
effects, is transported by P-glycoprotein [7]. 
Expression of human proteins in a heterologous host 
sometimes gives important information on their mecha- 
nisms of action. Schizosucchurom~~ces pombe (S. pombe) 
has been reported to have the MDRl homologue gene 
pmdl [Xl. Because the pmdl null mutant KN3, derived 
by gene disruption, was hypersensitive to the MDR- 
related drug actinomycin D, S. pombe KN3 was ex- 
pected to be useful as a host for expressing human 
P-glycoprotein to analyse its function. Thus. human 
P-glycoprotein was expressed in S. pombe KN3 and a 
functional comparison was done with P-glycoprotein 
expressed in human cultured cells. 
It is shown here that human P-glycoprotein confers 
on S. pombe resistance to valinomycin, a cyclic dode- 
capeptide antibiotic, and actinomycin D, but not to 
adriamycin. Because a mutant that was expected to be 
ATP-hydrolysis deficient did not confer resistance to 
valinomycin or actinomycin D, ATP hydrolysis is sug- 
gested to be necessary for extruding these agents out of 
cells. 
2. EXPERIMENTAL 
1.1 Cell culture and fransfectlon 
KB-3-l cells were transfected with a human P-glycoprotein expres- 
sion vector pSKGA [9], along with pSV2neo. Transfected cells were 
first selected m medium contaimng 0 8 mg/ml of G418. G418-resistant 
cells were pooled and selected for the expression of the ADA gene, 
which is contamed m pSKGA as a selectable marker, in 10 nM 
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2’-deoxycoformycm and 4 PM 9-/?-o-xylofuranosyl adenme for 
2 weeks. Several transformants were isolated and Insertion of the 
MDRl gene was confirmed by Southern blot analysis, One transfor- 
mant (KB-G?) was propagated m 200 ng/ml of vincrtstme to mamtam 
the high expresston of P-glycoprotein 
2.2 Cot1 Y~~I(L’~IO~Z of (1 S~.ht3oJuc.c,hurorIl?‘(.es pottrhe expression plustnid 
For the construction of an S potnhe expression plasmid. Sun and 
BurtzHI sites were created at the 5’ and 3’ ends of human weld-type 
MDRI cDNA just before the first ATG codon and just after the 
termination codon by the polymerase chain reactton (PCR) and lmker 
Insertion. respecttvely. Then MDRI cDNA was Inserted into San- 
BurnHI sites of pART1 vector, where the MDRI gene was under the 
control of the constttutive promoter of the udh gene. 
For the constructton of the ATP-hydrolyses deficient mutant, 
methionme was substituted for Iysme-433 as follows A PCR fragment 
generated with ohgonucleottdes GGGAAATTTGGAATTCAG (nt 
1167- 1184) and GCATCAGCTGGACTGTTGTGCTCATCCCAC- 
AGCC (nt 1321-1288) was digested with GoRI and PvuII. and was 
replaced with the correspondmg fragment of the full-length MDRI 
cDNA. 
To substttute asparttc acid for asparagme m three predtcted N- 
glycosylatton sites (asparagine-91, -94, and -99) of the full-length 
MDRl cDNA, site-directed mutagenesis was first done with the ol- 
tgonucleotide AGTGATATCGATGATACAGG (nt 285-305) to cre- 
ate a Cktl sate at nt 292. which also resulted m the mutagenests of the 




inserted into the &fll~ CkrI site of the full-length MDRI cDNA to 
mutagemze the other two glycosylation sites (asparagme-91 and -94). 
Drug sensitivity of cells was assayed by measurmg the mmimum 
inhibttory concentratton. The cells were grown m Edinburgh mimmal 
medium wtthout leucine to an OD,,,, of 0.4 The same number of cells 
were streaked on YPD plates containing vartous concentrations of 
each drug. and Incubated at 30°C for 5~ 7 days 
3. RESULTS AND DISCUSSION 
Although P-glycoprotein has been suggested to inter- 
act with some oligopeptides. interaction with peptide 
antibiotics is still obscure: MDR cells expressing P- 
glycoprotein have been reported to be resistant to gram- 
icidine D, a linear pentadeca-peptide, but resistance to 
valinomycin, a cyclic dodecapeptide. was very weak or 
marginal [lo]. Therefore, human MDR cell line KB-G2 
was established by introducing human MDRI cDNA 
isolated from a normal adrenal gland [ll] into drug- 
sensitive KB3-1 cells to examine the involvement of 
P-glycoprotein in the resistance to peptide antibiotics. 
KB-G2 cells, expressing human P-glycoprotein (Fig. 
la), showed a typical MDR phenotype. resistance to 
various drugs that have no structural similarity, includ- 
ing adriamycin (Table I) and actinomycin D (data not 
shown). KB-G2 also showed resistance to the peptide 
antibiotics valinomycin, gramicidin D, and alamcthicin. 







Fig. 1. Western blot of membrane fractions using monoclonal anti- 
body C219 as a probe for P-glycoprotein. 10 mg of crude membrane 
protein was put on each lane. (a) Lane 1, KB-3-l; lane 2. KB-G2; lane 
3, KB-NC1 (b) lane 4, KN3/pgp; lane 5, KN3; lane 6. KN3/pgpMK. 
Molecular stze standards are Indicated in kDa at the left 
come in the presence of excess verapamil, cepharanthin, 
or cyclosporine A, which are known as MDR modula- 
tors, as in the case of resistance to vinblastine. These 
results suggest that P-glycoprotein functions as an ef- 
flux pump of valinomycin and gramicidin D. 
KB-G2 did not show resistance to melitin. Melitin is 
a 26-amino acid peptide with a molecular weight of 
2,847. Because most substrates for P-glycoprotein are 
hydrophobic with molecular weights of around 1,000, 
melitin could be too large to be a substrate for P- 
glycoprotein. Alternatively, the amphipathic nature of 
melitin could be a reason, although KB-G2 did not 
show resistance to gramicidin S, a hydrophobic cyclic 
decapeptide (data not shown). It is not clear why resis- 
tance to alamethicin was not overcome in the presence 
of MDR modulators (Table I). 
Next we attempted to examine the function of human 
P-glycoprotein expressed in S. pombe KN3 as a host. S. 
pombe KN3lpgp expressing human P-glycoprotein 
showed resistance to actinomycin D and valinomycin 
but interestingly not to adriamycin (Table II). Because 
KN3 was not sensitive to other drugs examined, the 
difference of sensitivity could not be measured although 
KN3/pgp showed marginal resistance to VP16. We ex- 
amined the effect of the MDR modulators verapamil 
and cyclosporin A, but unexpectedly cyclosporin A (100 
mg/ml) did not overcome resistance of S. pornbr KN31 
pgp to valinomycin or actinomycin D (data not shown). 
Verapamil (100 mg/ml) showed a marginal effect on 
actinomycin D resistance (Table II), but did not show 
an obvious effect on valinomycin resistance (data not 
shown). This could be due to the poor penetration of the 
MDR modulators into the plasma membrane of S. 
pombe to interact with human P-glycoprotein. Because 
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Table I 
Relative resistance of KB-G2 cells expressing P-glycoprotein and effects of MDR modulators 
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Antibiotics 3-1 
- +Cyclosporm A +Cepharanthin +Verapamil 







1” 12 ndb nd 
1 93 0.9 2.9 
1 6.9 0.9 1.3 
1 104 0.2 0.5 
1 4.1 0.4 3.6 
1 0.7 nd nd 
nd nd nd nd 
0.9 3.8 0.8 2.9 
1.0 0.9 1.1 1.4 
0.8 18 0.9 1.8 
05 41 0.8 3.6 
nd nd 1.1 0.9 
The IC,, values of KB-G2 cells against each drugs were divided by those of the parent KB-3-1 cells in the absence or presence of 1 PM MDR 
modulators. 
* IC,, values of KB-3-1 cells: adriamycin. 18 ng/ml. vinblastine. 0.84 ng/ml. valinomycm. 0.52 ng/ml; gramtcidm D, 39 nglml; alamethicm. 1.7 ,@ml: 
melittin, 7.4 ,@ml. 
b not determined. 
S. pombe is tolerant to valinomycin and actinomycin D 
more than IOOO-fold when compared to KB-3-1 cells 
(Tables I and 11). it is plausible to assume that S. pombe 
is also tolerant to the MDR modulators. Alternatively, 
the membrane environment might affect the function of 
human P-glycoprotein, as discussed later. 
To confirm that the resistance to actinomycin D and 
valinomycin of KN3/pgp was dependent on the active 
et&x pump activity of human P-glycoprotein, we intro- 
duced a single amino acid substitution into human P- 
glycoprotein that is thought to abolish the ATPase ac- 
tivity and hence the drug transport activity 1121. S. 
pombe KN3lpgpMK expressing the mutant form of 
P-glycoprotein as much as the wild type in KN3/pgp 
(Fig. lb) did not show any resistance to these drugs 
(Table II). These results suggest that human P- 
glycoprotein functions as an efflux pump of actinomy- 
tin D and valinomycin in the membrane of S. pombe. 
Human P-glycoprotein expressed in S. pombe mi- 
Table II 
Drug sensitivity of Schlrosuccharotiz~ces pomhe expressing human 
P-glycoprotein 
Antibiotics KN3lvector KN3/pgp KN3/pgpMK 
Actinomycin D” 5 (I)’ 10 (2) 4 (0.8) 
+Verapamil (100 &ml) 5 (1) 7.5 (1.5) 
Valinomycin” 3 (1) 20 (6.7) 0.5 (0.2) 
Leptomycm Bb 6 (1) 6 (1) 
Adrtamycin” 75 (1) 75 (1) 
Gramicidin D” >150 >150 
VP16” 200 >200 
Puromycin” >200 >200 
The minimum Inhibitory concentration of KN3kector. KN3/pgp ex- 
pressing human P-glycoprotein and KN3/pgpMK expressing ATP- 
hydrolysis-deficient mutant were compared. 
“fig/ml. 
bng/ml. 
‘Values in parentheses are the resistance relative to that of KN3/ 
vector. 
grated faster than that expressed in human cultured 
cells (Fig. 1) and did not confer resistance to adriamy- 
tin. This apparent small molecular weight of human 
P-glycoprotein expressed in S. pomhe was considered to 
be due to the lack of glycosylation. because it has been 
reported that human P-glycoprotein expressed in S. cey- 
evisiue is not glycosylated properly [5.6.14]. Thus we 
examined the effects of glycosylation on the function of 
human P-glycoprotein by expressing a mutant in which 
asparagine in the consensus sequences of three pre- 
dicted N-glycosylation sites was replaced with aspartic 
acid. Although the human P-glycoprotein contains 10 
consensus sequences for N-linked glycosylation, only 
three are predicted to be exposed to the out of the cell 
in the putative first extracellular loop [13]. 
The N-glycosylation-deficient mutant was trans- 
fected into KB-331, and the stable transformant KB-Nl 
expressing P-glycoprotein without N-glycosylation was 
isolated (Fig. la). KB-Nl showed resistance to colchic- 
ine, vinblastine, vincristine, and adriamycin (data not 
shown). The absence of N-glycosylation did not alter 
the pattern of cross-resistance. 
These results suggest that other modifications than 
N-glycosylation or membrane circumstance affect the 
ability of human P-glycoprotein to confer resistance to 
adriamycin. We have reported previously that human 
P-glycoprotein expressed in S. cerevisiue did not confer 
adriamycin resistance or was not photoaffinity labeled 
by [‘Hlazidopine [14]. We have also reported that P- 
glycoprotein activity is dependent on the membrane en- 
vironment in a reconstituted system [ 151. The accumula- 
tion of drugs in a multidrug resistant cell line was re- 
cently reported to be sensitive to alteration of mem- 
brane properties [16]. These results suggest that the 
plasma membrane of S. pombe can support the interac- 
tion of P-glycoprotein with valinomycin and actinomy- 
tin D, but not with adriamycin. Valinomycin and acti- 
nomycin D contain a peptide moiety. P-glycoprotein 
also mediates export of a-factor mating peptide [6]. The 
281 
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interaction of substrates which contain a peptide moiety 
with P-glycoprotein might be different from that of 
other substrates. The success of transfer of valinomycin 
resistance to S. pornbe by human wild-type P-glycopro- 
tein. which seems ATP-hydrolysis-dependent, will facil- 
itate the analysis of the mechanism of P-glycoprotein 
function. 
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